Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aeglea Biothera (NQ: AGLE )

7.980 USD -0.230 (-2.80%)
Official Closing Price Updated: 4:21 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Aeglea Biothera

< Previous 1 2 3 4 5 6 7 8 Next >
Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer
Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and... 
From GlobeNewswire News Releases
Thursday Sector Laggards: Drugs, Shipping Stocks
In trading on Thursday, drugs shares were relative laggards, down on the day by about 2.9%. Helping drag down the group were shares of Aegerion Pharmaceuticals, down about 16.1% and shares of Aeglea... 
Tags Stocks
From Market News Video
BRIEF-Jennison Associates LLC reports 10.7 pct passive stake in Aeglea Biotherapeutics Inc as of April 30
* Jennison Associates LLC reports 10.7 pct passive stake in Aeglea Biotherapeutics Inc as of April 30, 2016 - SEC FILING Source text [http://1.usa.gov/24H2sM5] Further company coverage: (Bengaluru... 
Tags companyNews
From Reuters: Company News
Benzinga's Top Initiations
RBC Capital initiated coverage on Shell Midstream Partners LP (NYSE: SHLX) with a Outperform rating and a $47 price target. Shell ... 
Tags BANC SHLX AGLE
From Benzinga
Aeglea BioTherapeutics to Present New Data at American Association for Cancer Research (AACR) Annual Meeting
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and... 
From GlobeNewswire News Releases
Aeglea BioTherapeutics to Present New Data at American Association for Cancer Research (AACR) Annual Meeting
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and... 
From GlobeNewswire News Releases
BRIEF-Novartis AG reports a 17.2% pct passive stake in Aeglea Biotherapeutics Inc as of April 6, 2016 - SEC Filing
* Novartis AG reports a 17.2% pct passive stake in Aeglea Biotherapeutics Inc as of April 6, 2016 - SEC Filing Source text - http://1.usa.gov/1YwbYhd Further company coverage: (Bengaluru Newsroom: +1... 
Tags companyNews
From Reuters: Company News
Aeglea BioTherapeutics Announces Closing of Initial Public Offering and Partial Exercise of the Underwriters’ Option
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and... 
From GlobeNewswire News Releases
BRIEF-Aeglea biotherapeutics shares open at $10 in debut, flat with ipo price
* Shares open at $10 in debut, flat with ipo price of $10.00 Further company coverage: (Bengaluru Newsroom; +1 646 223 8780) 
Tags companyNews
From Reuters: Company News
Aeglea BioTherapeutics Announces Pricing of Initial Public Offering
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and... 
From Business Wire News Releases
Aeglea Biotherapeutics IPO: Wait For Larger April Deals
Aeglea Biotherapeutics Inc. expects to raise $51.4 million in its upcoming IPO. Based in Austin, Texas, Aeglea Biotherapeutics is a biotechnology company developing enzyme-based therapeutics to treat... 
Tags Healthcare Stocks / Equities
From Blogs - TalkMarkets
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.